Search Results

You are looking at 1 - 2 of 2 items for :

  • Author: Xue Luo x
Clear All Modify Search
Tian Zhou School of Clinical Medicine, GuiZhou Medical University, Guiyang, Guizhou, China
Department of Breast Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China

Search for other papers by Tian Zhou in
Google Scholar
PubMed
Close
,
Dai-wei Zhao School of Clinical Medicine, GuiZhou Medical University, Guiyang, Guizhou, China
Department of Surgery, Second People's Hospital of Guizhou Province, Guiyang, Guizhou, China

Search for other papers by Dai-wei Zhao in
Google Scholar
PubMed
Close
,
Ning Ma School of Clinical Medicine, GuiZhou Medical University, Guiyang, Guizhou, China

Search for other papers by Ning Ma in
Google Scholar
PubMed
Close
,
Xue-ying Zhu School of Clinical Medicine, GuiZhou Medical University, Guiyang, Guizhou, China

Search for other papers by Xue-ying Zhu in
Google Scholar
PubMed
Close
,
Xing-hong Chen Department of Surgery, Second People's Hospital of Guizhou Province, Guiyang, Guizhou, China

Search for other papers by Xing-hong Chen in
Google Scholar
PubMed
Close
,
Xue Luo Department of Breast Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China

Search for other papers by Xue Luo in
Google Scholar
PubMed
Close
,
Song Chen School of Clinical Medicine, GuiZhou Medical University, Guiyang, Guizhou, China

Search for other papers by Song Chen in
Google Scholar
PubMed
Close
, and
Qing-jun Gao Department of Thyroid Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China

Search for other papers by Qing-jun Gao in
Google Scholar
PubMed
Close

Objective

Thyroid cancer (THCA) is the most common endocrine cancer in the world. Although most patients with THCA have a good prognosis, the prognosis of those with THCA who have an extra-glandular invasion, vascular invasion, and distant metastasis is poor. Therefore, it is very important to find potential biomarkers that can effectively predict the prognosis and progression of highly aggressive THCAs. It has been identified that forkhead box P4 (FOXP4) may be a new biomarker for the proliferation and prognosis for tumor diagnosis. However, the expression and function of FOXP4 in THCA remain to be determined.

Methods

In the present study, the function of FOXP4 in cells was investigated through the comprehensive analysis of data in The Cancer Genome Atlas and combined with experiments including immunohistochemistry (IHC), colony formation, Cell Counting Kit-8 assay, wound scratch healing, and transwell invasion assay.

Results

In the present study, relevant bioinformatic data showed that FOXP4 was highly expressed in THCA, which was consistent with the results of the IHC and cell experiments. Meanwhile, 10 FOXP4-related hub genes were identified as potential diagnostic genes for THCA. It was found in further experiments that FOXP4 was located in the nucleus of THCA cells, and the expression of FOXP4 in the nucleus was higher than that in the cytoplasm. FOXP4 knockdown inhibited in vitro proliferation of the THCA cells, whereas overexpression promoted the proliferation and migration of THCA cells. Furthermore, deficiency of FOXP4 induced cell-cycle arrest.

Conclusion

FOXP4 might be a potential target for diagnosing and treating THCA.

Open access
Shi-en Fu Department of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China

Search for other papers by Shi-en Fu in
Google Scholar
PubMed
Close
,
Rou-mei Wang Department of Ultrasonic Diagnosis, The First Affiliated Hospital of Guangxi Medical University, Nanning, China

Search for other papers by Rou-mei Wang in
Google Scholar
PubMed
Close
,
Xing-huan Liang Department of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China

Search for other papers by Xing-huan Liang in
Google Scholar
PubMed
Close
,
Jing Xian Department of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China

Search for other papers by Jing Xian in
Google Scholar
PubMed
Close
,
Jie Pan Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China

Search for other papers by Jie Pan in
Google Scholar
PubMed
Close
,
Xue-lan Chen Department of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China

Search for other papers by Xue-lan Chen in
Google Scholar
PubMed
Close
,
Cheng-cheng Qiu Department of Ultrasonic Diagnosis, The First Affiliated Hospital of Guangxi Medical University, Nanning, China

Search for other papers by Cheng-cheng Qiu in
Google Scholar
PubMed
Close
,
Zhi-ping Tang Department of Ultrasonic Diagnosis, The First Affiliated Hospital of Guangxi Medical University, Nanning, China

Search for other papers by Zhi-ping Tang in
Google Scholar
PubMed
Close
,
Ying-fen Qin Department of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China

Search for other papers by Ying-fen Qin in
Google Scholar
PubMed
Close
,
Hai-yan Yang Department of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China

Search for other papers by Hai-yan Yang in
Google Scholar
PubMed
Close
,
Li-li Huang Department of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
Department of Endocrinology, The Affiliated Hospital of Guilin Medical University, Guilin, China

Search for other papers by Li-li Huang in
Google Scholar
PubMed
Close
,
Ya-qi Kuang Department of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China

Search for other papers by Ya-qi Kuang in
Google Scholar
PubMed
Close
,
Yan Ma Department of Ultrasonic Diagnosis, The First Affiliated Hospital of Guangxi Medical University, Nanning, China

Search for other papers by Yan Ma in
Google Scholar
PubMed
Close
, and
Zuo-jie Luo Department of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China

Search for other papers by Zuo-jie Luo in
Google Scholar
PubMed
Close

Introduction

Chronic thyrotoxic myopathy (CTM) is a common, easily neglected complication of hyperthyroidism. There are currently no standard diagnostic criteria for CTM, and the ultrasonic characteristics of CTM-affected skeletal muscle remain unclear. Herein, we aimed to evaluate hyperthyroid patients for CTM by ultrasound and identify ultrasonic muscle parameter cutoffs for CTM diagnosis.

Materials and methods

Each participant underwent ultrasonography. The original (muscle thickness (MT), pennation angle (PA), and cross-sectional area (CSA)) and corrected (MT/height (HT), MT/body mass index (BMI), CSA/HT, and CSA/BMI) parameters of the vastus lateralis and vastus medialis (VM) were evaluated. The diagnostic effectiveness of ultrasound for predicting CTM was determined using receiver operating characteristic (ROC) curve analysis. Our study included 203 participants: 67 CTM patients (18 males, 49 females), 67 non-CTM patients (28 males, 39 females) and 69 healthy controls (20 males, 49 females).

Results

The CTM group had lower muscular ultrasonic and anthropometric parameters, higher thyroid hormone and thyroid-stimulating hormone receptor antibody (TRAb) levels, and a longer duration of hyperthyroidism than the non-CTM group (P < 0.05). The VM-PA, VM-CSA, VM-CSA/HT, and VM-CSA/BMI were lower in females than in males (P < 0.05). Free thyroxine (FT4) and TRAb both showed significant negative correlations with VM-MT, VM-MT/HT, VM-CSA, and VM-CSA/HT (P < 0.05). VM-MT/BMI and VM-CSA/HT, respectively, best predicted male and female CTM (AUC = 0.84, 0.85; cutoff ≤ 0.07, < 4.01).

Conclusion

Ultrasound measurement of muscular parameters, especially in the VM, is a valid and feasible way of diagnosing and characterizing possible CTM in hyperthyroidism.

Open access